Trial reportEye (London, England)2025
Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial.
Trial report in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Short-term efficacy of increasing 0.01% atropine administration frequency in controlling myopia progression in adolescents.BMC ophthalmology · 2026Article
- Effectiveness of Low-Dose Atropine Combined With Bright Light Therapy for Controlling Myopic Eye Growth in Schoolchildren: Study Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate the efficacy and safety of standard 0.01% atropine at different frequencies (twice daily versus once nightly) for myopia progression.
methodsIn this randomised controlled trial (ChiCTR2200055532), Participants aged 6-13 years with a spherical equivalent (SE) between -6.00 to -0.75D and a best corrected visual acuity of ≥0.8 were enrolled and randomised 1:1 to receive 0.01% atropine eye drops once nightly (QD group) or twice daily (BID group) for one year. The primary endpoint was the change in axial length (AL) after one year.
resultsSeventy participants were included and assigned to the QD (n = 34) and BID (n = 36) groups, respectively. After one year, the BID group exhibited a significantly smaller increase in mean AL compared with the QD group (0.21 ± 0.18 vs. 0.32 ± 0.14 mm, P = 0.002), corresponding to a 34% reduction in axial elongation. The BID regimen was 53% more effective in slowing SE progression than the QD regimen, with mean SE changes of -0.31 ± 0.50 vs. -0.66 ± 0.37D (P < 0.001). Safety parameters (e.g., amplitude of accommodation, tear film stability, intraocular pressure) remained similar between the two groups (all P > 0.05). Although mesopic pupil diameter (PD) increased more in the BID group (0.65 ± 0.63 vs. 0.27 ± 0.69 mm, P = 0.010), the difference was clinically acceptable and not observed in photopic PD (P = 0.297).
conclusionTwice-daily administration of 0.01% atropine significantly enhances the management of axial elongation and SE progression compared with once-nightly dosing without increasing the risk of adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.